Famciclovir for the treatment of recurrent genital herpes: a clinical and pharmacological perspective

Bibliography

• MERTZ KJ, TREES D, LEVINE WC et al.: Aetiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J. Infect. Dis. (1998) 178:1795-1798.
   PubMed Web of Science ®Google Scholar
• RISBUD A, CHAN-TACK K, GADKARI D et al.: The aetiology of genital ulcer disease by multiplex polymerase chain reaction and relationship to HIV infection among patients attending sexually transmitted disease clinics in Pune, India. Sex. Transm. Dis. (1999) 26:55-62.
   PubMedGoogle Scholar
• AHMED HJ, MBWANA J, GUNNARSSON E et al.: Aetiology of genital ulcer disease and association with human immunodeficiency virus infection in two Tanzanian cities. Sex. Transm. Dis. (2003) 30:114-119.
   PubMedGoogle Scholar
• BRUISTEN SM, CAIRO I, FENNEMA H et al.: Diagnosing genital ulcer disease in a clinic for sexually transmitted diseases in Amsterdam, The Netherlands. J. Clin. Microbiol. (2001) 39:601-605.
   PubMedGoogle Scholar
• JENKINS FJ, ROWE DT, RINALDO CR Jr: Herpesvirus infections in organ transplant recipients. Clin. Diagn. Lab. Immunol. (2003) 10:1-7.
   PubMedGoogle Scholar
• FLEMING DT, MCQUILLAN GM, JOHNSON RE et al.: Herpes simplex virus Type 2 in the United States, 1976 to 1994. N. Engl. J. Med. (1997) 16:1105-1111.
   Google Scholar
• DIAZ-MITOMA F, SIBBALD RG, SHAFRAN SD et al.: Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. JAMA (1998) 280:887-892.
   PubMed Web of Science ®Google Scholar
• LAFFERTY WE, DOWNEY L, CELUM C et al.: Herpes simplex virus Type 1 as a cause of genital herpes: impact on surveillance and prevention. J. Infect. Dis. (2000) 181:1454-1457.
   PubMed Web of Science ®Google Scholar
• WHITLEY RJ, KIMBERLIN DW, ROIZMAN B: Herpes simplex viruses. Clin. Infect. Dis. (1998) 26:541-553.
   PubMed Web of Science ®Google Scholar
• KIMBERLIN DW, ROUSE DJ: Clinical practice. Genital herpes. N. Engl. J. Med. (2004) 350:1970-1977.
   PubMedGoogle Scholar
• BENEDETTI J, COREY L, ASHLEY R: Recurrence rates in genital herpes after symptomatic first-episode infection. Ann. Intern. Med. (1994) 121:847-854.
   PubMed Web of Science ®Google Scholar
• BENEDETTI JK, ZEH J, COREY L: Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann. Intern. Med. (1999) 131:14-20.
   PubMedGoogle Scholar
• ENGELBERG R, CARRELL D, KRANTZ E et al.: Natural history of genital herpes simplex virus Type 1 infection. Sex. Transm. Dis. (2003) 30:174-177.
   PubMed Web of Science ®Google Scholar
• WALD A, ZEH J, SELKE S et al.: Reactivation of genital herpes simplex virus Type 2 infection in asymptomatic seropositive persons. N. Engl. J. Med. (2000) 342:844-850.
   PubMed Web of Science ®Google Scholar
• KOELLE DM, BENEDETTI J, LANGENBERG A et al.: Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann. Intern. Med. (1992) 116:433-437.
   PubMed Web of Science ®Google Scholar
• EARNSHAW DL, BACON TH, DARLISON SJ et al.: Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus Type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob. Agents Chemother. (1992) 36:2747-2757.
   PubMed Web of Science ®Google Scholar
• VERE HODGE RA, PERKINS RM: Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob. Agents Chemother. (1989) 33:223-229.
   PubMedGoogle Scholar
• PERRY CM, WAGSTAFF AJ: Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs (1995) 50:396-415.
   PubMed Web of Science ®Google Scholar
• WEINBERG A, BATE BJ, MASTERS HB et al.: In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2. Antimicrob. Agents Chemother. (1992) 36:2037-2038.
   PubMed Web of Science ®Google Scholar
• BOYD MR, BACON TH, SUTTON D: Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals. Antimicrob. Agents Chemother. (1988) 32:358-363.
   PubMed Web of Science ®Google Scholar
• VERE HODGE RA, SUTTON D, BOYD MR et al.: Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob. Agents Chemother. (1989) 33:1765-1773.
   PubMedGoogle Scholar
• STEIN GE: Pharmacology of new antiherpes agents: famciclovir and valacyclovir. J. Am. Pharm. Assoc. (1997) NS37:157-163.
   Google Scholar
• BACON TH, BOYD MR: Activity of penciclovir against Epstein-Barr virus. Antimicrob. Agents Chemother. (1995) 39:1599-1602.
   PubMed Web of Science ®Google Scholar
• SHEN H, ALSATIE M, ECKERT G et al.: Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection. Clin Gastroenterol. Hepatol. (2004) 2:330-336.
   PubMedGoogle Scholar
• THACKRAY AM, FIELD HJ: Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. J. Infect. Dis. (1996) 173:291-299.
   PubMed Web of Science ®Google Scholar
• THACKRAY AM, FIELD HJ: Famciclovir and valaciclovir differ in the prevention of herpes simplex virus Type 1 latency in mice: a quantitative study. Antimicrob. Agents Chemother. (1998) 42:1555-1562.
   PubMed Web of Science ®Google Scholar
• FIELD HJ, TEWARI D, SUTTON D et al.: Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus Type 1 in a murine immunosuppression model. Antimicrob. Agents Chemother. (1995) 39:1114-1119.
   PubMed Web of Science ®Google Scholar
• LOUTSCH JM, SAINZ B JR, MARQUART ME et al.: Effect of famciclovir on herpes simplex virus Type 1 corneal disease and establishment of latency in rabbits. Antimicrob. Agents Chemother. (2001) 45:2044-2053.
   PubMedGoogle Scholar
• THACKRAY AM, FIELD HJ: Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus Type 2 in a murine infection model. Antimicrob. Agents Chemother. (1996) 40:846-851.
   PubMed Web of Science ®Google Scholar
• THACKRAY AM, FIELD HJ: Persistence of infectious herpes simplex virus Type 2 in the nervous system in mice after antiviral chemotherapy. Antimicrob. Agents Chemother. (2000) 44:97-102.
   PubMedGoogle Scholar
• PROBER CG: Herpesvirus infections: from bedside to bench and back again. Herpes (2001) 8:3.
   Google Scholar
• STANBERRY LR, KERN ER, RICHARDS JT et al.: Genital herpes in guinea-pigs: pathogenesis of the primary infection and description of recurrent disease. J. Infect. Dis. (1982) 146(3):397-404.
   PubMed Web of Science ®Google Scholar
• SCRIBA M: Herpes simplex virus infection in guinea-pigs: an animal model for studying latent and recurrent herpes simplex virus infection. Infect. Immun. (1975) 12:162-165.
   PubMedGoogle Scholar
• JENNINGS R, SMITH TL, MYHREN F et al.: Evaluation of a novel, antiherpes simplex virus compound, acyclovir elaidate (P-4010), in the female guinea-pig model of genital herpes. Antimicrob. Agents Chemother. (1999) 43:53-61.
   PubMedGoogle Scholar
• SARISKY RT, BACON TH, BOON RJ et al.: Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials. Arch. Virol. (2003) 148:1757-1769.
   PubMed Web of Science ®Google Scholar
• SARISKY RT, QUAIL MR, CLARK PE et al.: Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir. J. Virol. (2001) 75:1761-1769.
   PubMed Web of Science ®Google Scholar
• COEN DM, SCHAFFER PA: Two distinct loci confer resistance to acycloguanosine in herpes simplex virus Type 1. Proc. Natl. Acad. Sci. USA (1980) 77:2265-2269.
   PubMed Web of Science ®Google Scholar
• SCHNIPPER LE, CRUMPACKER CS: Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proc. Natl. Acad. Sci. USA (1980) 77:2270 -2273.
   PubMed Web of Science ®Google Scholar
• CHIBO D, DRUCE J, SASADEUSZ J et al.: Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus. Antiviral Res. (2004) 61:83-91.
   PubMedGoogle Scholar
• BOYD MR, BACON TH, SUTTON D et al.: Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob. Agents Chemother. (1987) 31:1238-1242.
   PubMed Web of Science ®Google Scholar
• THUST R, SCHACKE M, WUTZLER P: Cytogenetic genotoxicity of antiherpes virostatics in Chinese hamster V79-E cells. I. Purine nucleoside analogues. Antiviral Res. (1996) 31:105-113.
   PubMed Web of Science ®Google Scholar
• PUE MA, PRATT SK, FAIRLESS AJ et al.: Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J. Antimicrob. Chemother. (1994) 33:119-127.
   PubMed Web of Science ®Google Scholar
• MOOMAW MD, CORNEA P, RATHBUN RC et al.: Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster. Expert Rev. Anti-Infect. Ther. (2003) 1:283-295.
   PubMedGoogle Scholar
• PUE MA, BENET LZ: Pharmacokinetics of famciclovir in man. Antiviral Chem. Chemother. (1993) 4:47-55.
   Web of Science ®Google Scholar
• FILER CW, ALLEN GD, BROWN TA et al.: Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects. Xenobiotica (1994) 24:357-368.
   PubMed Web of Science ®Google Scholar
• FOWLES SE, PIERCE DM, PRINCE WT et al.: The tolerance to and pharmacokinetics of penciclovir (BRL 39,123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. Eur. J. Clin. Pharmacol. (1992) 43:513-516.
   PubMed Web of Science ®Google Scholar
• BOIKE SC, PUE MA, FREED MI et al.: Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment. Clin. Pharmacol. Ther. (1994) 55:418-426.
   PubMedGoogle Scholar
• GILL KS, WOOD M: The clinical pharmacokinetics of famciclovir. Clin. Pharmacokinet. (1996) 31:1-8.
   PubMed Web of Science ®Google Scholar
• BOIKE SC, PUE M, AUDET PR et al.: Pharmacokinetics of famciclovir in subjects with chronic hepatic disease. J. Clin. Pharmacol. (1994) 34:1199-1207.
   PubMed Web of Science ®Google Scholar
• OBACH RS: Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab. Dispos. (2004) 32:89-97.
   PubMed Web of Science ®Google Scholar
• AL-SALMY HS. Individual variation in hepatic aldehyde oxidase activity. IUBMB Life (2001) 51:249-253.
   PubMed Web of Science ®Google Scholar
• FOWLES SE, PRATT SK, LAROCHE J et al.: Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers. Eur. J. Clin. Pharmacol. (1994) 46:355-359.
   PubMedGoogle Scholar
• LASKIN OL, DE MIRANDA P, KING DH et al.: Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob. Agents Chemother. (1982) 21:804-807.
   PubMed Web of Science ®Google Scholar
• DE BONY F, TOD M, BIDAULT R et al.: Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob. Agents Chemother. (2002) 46:458-463.
   PubMed Web of Science ®Google Scholar
• TYRING S, BELANGER R, BEZWODA W et al.: A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest. (2001) 19:13-22.
   PubMed Web of Science ®Google Scholar
• FOWLES SE, PUE MA, DM P et al.: Pharmacokinetics of penciclovir in healthy elderly subjects following a single oral administration of 750 mg famciclovir. Br. J. Clin. Pharmacol. (1992) 34:450P.
   Google Scholar
• SACKS SL, AOKI FY, DIAZ-MITOMA F et al.: Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA (1996) 276:44-49.
   PubMed Web of Science ®Google Scholar
• SACKS SL, AOKI FY, MARTEL AY et al.: Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial. Clin. Infect. Dis. (2005) 41:1097-1104.
   PubMed Web of Science ®Google Scholar
• CHOSIDOW O, DROUAULT Y, LECONTE-VEYRIAC F et al.: Famciclovir versus aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br. J. Dermatol. (2001) 144:818-824.
   PubMed Web of Science ®Google Scholar
• WORKWOWSKI KA, LEVINE WC, CENTERS FOR DISEASE CONTROL AND PREVENTION: Sexually Transmitted Diseases Treatment Guidelines 2002. MMWR Recomm. Rep. (2002) 51:1-78.
   Google Scholar
• AOKI FY, TYRING S, DIAZ-MITOMA F et al.: Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. (2006) 42:8-13.
   PubMed Web of Science ®Google Scholar
• REICHMAN RC, BADGER GJ, MERTZ GJ et al.: Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA (1984) 251:2103-2107.
   PubMed Web of Science ®Google Scholar
• MERTZ GJ, ERON L, KAUFMAN R et al.: Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection. Am. J. Med. (1988) 85:14-19.
   PubMed Web of Science ®Google Scholar
• MERTZ GJ, LOVELESS MO, LEVIN MJ et al.: Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch. Intern. Med. (1997) 157:343-349.
   PubMed Web of Science ®Google Scholar
• AOKI FY: Management of genital herpes in HIV-infected patients. Herpes (2001) 8:41-45.
   PubMedGoogle Scholar
• WALD A, ZEH J, SELKE S et al.: Virologic characteristics of subclinical and symptomatic genital herpes infections. N. Engl. J. Med. (1995) 333:770-775.
   PubMed Web of Science ®Google Scholar
• WALD A, ZEH J, SELKE S et al.: Genital shedding of herpes simplex virus among men. J. Infect. Dis. (2002) 186:S34-S39.
   PubMedGoogle Scholar
• KRONE MR, WALD A, TABET SR et al.: Herpes simplex virus Type 2 shedding in human immunodeficiency virus-negative men who have sex with men: frequency, patterns, and risk factors. Clin. Infect. Dis. (2000) 30:261-267.
   PubMedGoogle Scholar
• WALD A, HUANG ML, CARRELL D et al.: Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J. Infect. Dis. (2003) 188:1345-1351.
   PubMed Web of Science ®Google Scholar
• WALD A, LANGENBERG AG, LINK K et al.: Effect of condoms on reducing the transmission of herpes simplex virus Type 2 from men to women. JAMA (2001) 285:3100-3106.
   PubMed Web of Science ®Google Scholar
• WALD A, ZEH J, BARNUM G et al.: Suppression of subclinical shedding of herpes simplex virus Type 2 with acyclovir. Ann. Intern. Med. (1996) 124:8-15.
   PubMed Web of Science ®Google Scholar
• GUPTA R, WALD A, KRANTZ E et al.: Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J. Infect. Dis. (2004) 190:1374-1381.
   PubMed Web of Science ®Google Scholar
• SACKS SL: Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial. J. Infect. Dis. (2004) 189:1341-1347.
   PubMed Web of Science ®Google Scholar
• WALD A, SELKE S, WARREN T et al.: Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex. Transm. Dis. (2006) 33(9):529-533.
   PubMed Web of Science ®Google Scholar
• COREY L, WALD A, PATEL R et al.: Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. (2004) 350:11-20.
   PubMed Web of Science ®Google Scholar
• SCHACKER T, RYNCARZ AJ, GODDARD J et al.: Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA (1998) 280:61-66.
   PubMed Web of Science ®Google Scholar
• KREISS JK, COOMBS R, PLUMMER F et al.: Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J. Infect. Dis. (1989) 160:380-384.
   PubMed Web of Science ®Google Scholar
• GRAY RH, WAWER MJ, BROOKMEYER R et al.: Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet (2001) 357:1149-1153.
   PubMed Web of Science ®Google Scholar
• HENG MC, HENG SY, ALLEN SG: Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet (1994) 343:255-258.
   PubMed Web of Science ®Google Scholar
• ALBRECHT MA, DELUCA NA, BYRN RA et al.: The herpes simplex virus immediate-early protein, ICP4, is required to potentiate replication of human immunodeficiency virus in CD4+ lymphocytes. J. Virol. (1989) 63:1861-1868.
   PubMed Web of Science ®Google Scholar
• GOLDEN MP, KIM S, HAMMER SM et al.: Activation of human immunodeficiency virus by herpes simplex virus. J. Infect. Dis. (1992) 166:494-499.
   PubMedGoogle Scholar
• MOLE L, RIPICH S, MARGOLIS D et al.: The impact of active herpes simplex virus infection on human immunodeficiency virus load. J. Infect. Dis. (1997) 176:766-770.
   PubMed Web of Science ®Google Scholar
• DUFFUS WA, MERMIN J, BUNNELL R et al.: Chronic herpes simplex virus type-2 infection and HIV viral load. Int. J. STD AIDS (2005) 16:733-735.
   PubMed Web of Science ®Google Scholar
• SIEGAL FP, LOPEZ C, HAMMER GS et al.: Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N. Engl. J. Med. (1981) 305:1439-1444.
   PubMed Web of Science ®Google Scholar
• BAGDADES EK, PILLAY D, SQUIRE SB et al.: Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS (1992) 6:1317-1320.
   PubMedGoogle Scholar
• AUGENBRAUN M, FELDMAN J, CHIRGWIN K et al.: Increased genital shedding of herpes simplex virus Type 2 in HIV-seropositive women. Ann. Intern. Med. (1995) 123:845-847.
   PubMedGoogle Scholar
• AUGENBRAUN M, COREY L, REICHELDERFER P et al.: Herpes simplex virus shedding and plasma human immunodeficiency virus RNA levels in coinfected women. Clin. Infect. Dis. (2001) 33:885-890.
   PubMedGoogle Scholar
• SCHACKER T, ZEH J, HU HL et al.: Frequency of symptomatic and asymptomatic herpes simplex virus Type 2 reactivations among human immunodeficiency virus-infected men. J. Infect. Dis. (1998) 178:1616-1622.
   PubMed Web of Science ®Google Scholar
• SULIGOI B, DORRUCCI M, VOLPI A et al.: No protective effect of acyclovir on HIV disease progression in a cohort of HSV-2-HIV-infected individuals. Antivir. Ther. (2002) 7:289-291.
   PubMedGoogle Scholar
• ROMANOWSKI B, AOKI FY, MARTEL AY et al.: Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group. AIDS (2000) 14:1211-1217.
   PubMed Web of Science ®Google Scholar
• SCHACKER T, HU HL, KOELLE DM et al.: Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann. Intern. Med. (1998) 128:21-28.
   PubMed Web of Science ®Google Scholar
• DEJESUS E, WALD A, WARREN T et al.: Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J. Infect. Dis. (2003) 188:1009-1016.
   PubMed Web of Science ®Google Scholar
• CHEN KT, SEGU M, LUMEY LH et al.: Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus. Obstet. Gynecol. (2005) 106:1341-1348.
   PubMed Web of Science ®Google Scholar
• BROWN Z: Preventing herpes simplex virus transmission to the neonate. Herpes (2004) 11:175A-186A.
   PubMedGoogle Scholar
• AOKI FY: Canadian Guidelines on Sexually Transmitted Infections, 2006 Edition: Genital Herpes Simplex Virus (HSV) Infections. Public Health Agency of Canada (2006).
   Google Scholar
• ANDREWS WW, KIMBERLIN DF, WHITLEY R et al.: Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. Am. J. Obstet. Gynecol. (2006) 194:774-781.
   PubMed Web of Science ®Google Scholar
• AVGIL M, ORNOY A: Herpes simplex virus and Epstein-Barr virus infections in pregnancy: consequences of neonatal or intrauterine infection. Reprod. Toxicol. (2006) 21:436-445.
   PubMed Web of Science ®Google Scholar
• MALKIN JE: Herpes Simplex Virus Infection in Pregnancy. Herpes (1999) 6:50-54.
   Google Scholar
• HUTTO C, ARVIN A, JACOBS R et al.: Intrauterine herpes simplex virus infections. J. Pediatr. (1987) 110:97-101.
   PubMed Web of Science ®Google Scholar
• BALDWIN S, WHITLEY RJ: Intrauterine herpes simplex virus infection. Teratology (1989) 39:1-10.
   PubMedGoogle Scholar
• BROWN ZA, SELKE S, ZEH J et al.: The acquisition of herpes simplex virus during pregnancy. N. Engl. J. Med. (1997) 337:509-515.
   PubMed Web of Science ®Google Scholar
• SALTZMAN R, JUREWICZ R, BOON R: Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob. Agents Chemother. (1994) 38:2454-2457.
   PubMed Web of Science ®Google Scholar
• BELL WR, CHULAY JD, FEINBERG JE: Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (1997) 76:369-380.
   PubMed Web of Science ®Google Scholar
• RIVAUD E, MASSIANI MA, VINCENT F et al.: Valacyclovir hydrochloride therapy and thrombotic thrombocytopenic purpura in an HIV-infected patient. Arch. Intern. Med. (2000) 160:1705-1706.
   PubMedGoogle Scholar
• SACKS SL, BISHOP AM, FOX R et al.: A double-blind, placebo (PLB)-controlled trial of the effect of chronically administered oral famciclovir (FCV; BRL 42810) on sperm production in men with recurrent genital herpes (RGH) infection. Antivir. Res. (1994) 23:72.
   Google Scholar
• NOVARTIS PHARMACEUTICALS CORP.: Famvir (famciclovir) prescribing information. East Hanover (NJ) USA (2002).
   Google Scholar
• MOORE HL JR, SZCZECH GM, RODWELL DE et al.: Preclinical toxicology studies with acyclovir: teratologic, reproductive and neonatal tests. Fundam. Appl. Toxicol. (1983) 3:560-568.
   PubMedGoogle Scholar
• STONE KM, REIFF-ELDRIDGE R, WHITE AD et al.: Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the International Acyclovir Pregnancy Registry, 1984-1999. Birth Defects Res. A Clin. Mol. Teratol. (2004) 70:201-207.
   PubMed Web of Science ®Google Scholar
• TYRING SK, BAKER D, SNOWDEN W: Valacyclovir for herpes simplex infection: long-term safety and sustained efficacy after 20 years experience with acyclovir. J. Inf. Dis. (2002) 186:S40-S46.
   PubMed Web of Science ®Google Scholar